Steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 September 2004 please refer to module 8B 
• 
• 
• 
• 
• 
• 
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  29  December  1998  an 
application  for  one  type  I  variation  falling  within  the  scope  of  item  No  8  of  Annex  I  to 
Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder 
applied for: 
A change in the qualitative composition of immediate packaging material. 
On 05 February 1999, the EMEA approved the variation. This variation required amendments 
to annexes I and IIIB of the Commission Decision. Revised EMEA notification dated 01 April 
1999 regarding EU numbers. The European Commission amended the Decision on 11 June 
1999. 
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  04  February  1999  an 
application  for  one  type  I  variation  falling  within  the  scope  of  item  No  1  of  Annex  I  to 
Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder 
applied for: 
An alternative manufacturing site for the finished product. 
On 22 March 1999, the EMEA approved the variation. This variation required amendments to 
annexes  II  and  IIIB  of  the  Commission  Decision..  The  European  Commission  amended  the 
Decision on 16 July 1999.  
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  04  February  1999  an 
application  for  one  type  I  variation  falling  within  the  scope  of  item  No  16  of  Annex  I  to 
Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder 
applied for: 
A change in the batch size of the finished product. 
On  22  March  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require  any 
amendment to the Commission Decision. 
The Marketing Authorisation Holder submitted to the EMEA on 08 April 1999 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No  32  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
A new engraving on the tablets. 
On  13  May  1999,  the  EMEA  approved  the  variation.  This  variation  required  amendments  to 
annexes  I  and  IIIB  of  the  Commission  Decision.  The  European  Commission  amended  the 
Decision on 08 July 1999.  
The Marketing Authorisation Holder submitted to the EMEA on 08 April 1999 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No  14  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
A change in the specification of the active substance. 
On  06  July  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require  any 
amendment to the Commission Decision. 
On 26 April 1999, the Marketing Authorisation Holder submitted a Type II variation application 
in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as 
amended.  The  scope  of  the  variation  related  to  the  update  of  the  Summaries  of  Product 
Characteristics and Package Leaflets according to the assessment of the second PSUR  
On  20  May  1999  the  CPMP  approved  the  variation.  The  variation  required  amendments  in 
annexes  I  and  IIIB  of  the  Commission  Decision.  The  European  Commission  amended  the 
Decision on 07 September 1999. 
1/3 
 
 
 
 
 
• 
• 
• 
• 
• 
Between 31 August 1999 and 4 May 2000, the EMEA issued Notifications for the approval of 
five type I variations concerning 
- 
- 
change in the manufacturer of the active substance, 
change in the batch size of the active substance, 
-  minor change of manufacturing process of the active substance, 
- 
- 
change in the manufacturer of the active substance, 
change  of  the  manufacturing  site  for  part  of  the  manufacturing  process  of  the  medicinal 
product. 
These variations did not require any amendment to the Commission decision. 
On  07  February  2000,  the  Marketing  Authorisation  Holder  submitted  a  Type  II  variation 
application  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10 
March 1995, as amended. The scope of the variation related to the update of the Summaries of 
Product Characteristics according to the assessment of the fourth PSUR. On 12 April 2000 the 
CPMP approved the variation. At the same time, annex II of the Commission Decision has been 
updated. The variation required amendments in annexes I and II of the Commission Decision. 
The European Commission amended the Decision on 13 July 2000.  
On 15 May 2000, the Marketing Authorisation Holder submitted a Type II variation application 
in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as 
amended. The Marketing Authorisation Holder applied for a new formulation of the film-coated 
tablet containing a new polymorphic form of the active substance. In addition to the subsequent 
changes in the SPC, Labelling and PL, these annexes have been revised according to the latest 
templates.  On  21  September  2000  the  CPMP  approved  the  variation.  The  variation  required 
amendments  in  annexes  I,  IIIA  and  IIIB  of  the  Commission  Decision.  The  European 
Commission amended the Decision on 15 January 2001.  
On  26  July  2000,  the  Marketing  Authorisation  Holder  requested  to  introduce  changes  to  an 
aspect of the labelling not connected to the Summary of Product Characteristics, by means of a 
Notification under Article 10(3) of Directive 92/27/EEC. Following EMEA’s Notification on 1 
August 2000, the European Commission amended the Decision (Annex IIIA) on 25 September 
2000.  
On  5  September  2000,  the  Marketing  Authorisation  Holder  submitted  a  Type  II  variation 
application  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10 
March 1995, as amended. The Marketing Authorisation Holder applied for an update of the SPC 
following the assessment of a PSUR. On 16 November 2000 the CPMP approved the variation. 
The  variation  required  amendments  in  annexes  I  and  IIIB  of  the  Commission  Decision.  The 
European Commission amended the Decision on 6 March 2001. 
2/3 
 
 
 
 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion 
issued on2 
Update of Summary of Product Characteristics (sections 4.4, 4.5 and 
4.8) andPackage Leaflet following the assessment of the 5th PSUR. 
Batch size of active substance 
Minor change of manufacturing process of the active substance 
Change in the name of a manufacturer of the active substance 
Update of the Summary of Product Characteristics and Package 
Leaflet 
Change in the name and/or address of the marketing authorisation 
holder 
Additonal indication (Acute Coronary Syndrome) 
Change following modification(s) of the manufacturing 
authorisation(s) 
Change in or addition of manufacturing site(s) for part or all of the 
manufacturing process 
Change in the name of a manufacturer of the medicinal product 
Extension of shelf-life as foreseen at time of authorisation 
Change in test procedure for starting material/intermediate used in 
manuf. of active substance 
Batch size of active substance 
Change in the batch size of finished product 
Minor changes in manufacture of the medicinal product 
Change in pack size for a medicinal product 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification) 
Renewal 
Change(s) to the manufacturing process for the active substance 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification) 
Update of Summary of Product Characteristics and Package Leaflet 
Replacement/add. of manufacturing site: Secondary packaging site 
and change in BR/QC testing - repl./add. manuf. responsible for BR 
- not incl. BC/testing 
II/0016 
I/0017 
I/0018 
I/0019 
II/0020 
I/0021 
II/0022 
I/0023 
I/0025 
I/0026 
I/0027 
I/0028 
I/0029 
I/0030 
I/0031 
I/0032 
N/0034 
R/0035 
II/0036 
N/0037 
II 
I 
I  
I 
II 
I 
II 
I 
I 
I 
I 
I 
I 
I 
I 
I 
N 
R 
II 
N 
II/0038 
IA/0039 
II 
IA 
Commission 
Decision 
Issued/amen
ded on 
16.07.01 
N/A 
N/A 
N/A 
29.03.01 
04.03.01 
04.03.04 
19.07.01 
23.08.01 
29.01.02 
03.10.01 
19.02.02 
28.05.02 
13.12.01 
09.09.02 
19.02.02 
16.05.02 
19.06.02 
27.05.02 
20.12.02 
19.02.03 
10.01.03 
27.03.03 
27.03.03 
14.02.03 
04.04.03 
22.05.03 
25.09.03 
20.11.03 
03.06.04 
11.06.04 
27.05.02 
03.02.03 
03.03.03 
16.01.03 
01.04.03 
01.04.03 
20.03.03 
12.05.03 
08.10.03 
02.10.03 
22.12.03 
02.08.04 
- 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
3/3 
 
 
 
 
 
 
 
 
                                                            
 
